Expression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) associated with poor survival in gastric cancer.
Altered expression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) was associated with human carcinogenesis and progression. This study assessed eIF5A-2 expression in gastric cancer tissues for association with clinicopathological parameters and survival of patients. A total of 436 gastric cancer tissues and 92 normal mucosal blocks were collected for construction of tissue microarrays and immunohistochemical assessment of eIF5A-2 expression. The data were statistically analyzed for association with clinicopathological factors and survival of patients. Immunohistochemical data showed that eIF5A-2 protein was highly expressed in gastric cancer tissues (p < 0.001). Upregulated expression of eIF5A-2 protein was associated with tumor Lauren classification, size, location, invasion, TNM stages, and lymph node and distant metastases. The 3- and 5-year cumulative survival rates of these 436 patients were 88.5 and 58.1 %, respectively. In contrast, the mean survival time of patients with increased tumor eIF5A-2 was 30.22 ± 1.23 vs. 51.29 ± 0.86 months for those with low tumor eIF5A-2 (p < 0.001). Multivariate analysis showed that eIF5A-2 expression and related tumor parameters were independent indicators of overall survival in gastric cancer patients. In conclusion, the current study indicates that overexpression of eIF5A-2 protein was associated with poor overall survival of gastric cancer patients.
Wenzhou Medical University, Wenzhou, China.|Department of Gastrointestinal Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.
Qiong
Q
Yang
Wenzhou Medical University, Wenzhou, China. zaiyuanye@163.com.|Department of Gastrointestinal Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China. zaiyuanye@163.com.
Zaiyuan
Z
Ye
Department of Gastrointestinal Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.
Qi
Q
Zhang
Department of Gastrointestinal Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China. zhaozhongsheng1950@163.com.
Zhongsheng
Z
Zhao
Department of Gastrointestinal Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.
Hongjun
H
Yuan
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D045744:Cell Line, Tumor; D015331:Cohort Studies; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009362:Neoplasm Metastasis; D010448:Peptide Initiation Factors / Q000378:metabolism*; D011379:Prognosis; D016016:Proportional Hazards Models; D016601:RNA-Binding Proteins / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000378:metabolism* / Q000401:mortality; D046888:Tissue Array Analysis; D016896:Treatment Outcome; D015854:Up-Regulation; D000097574:Eukaryotic Translation Initiation Factor 5A
D010448:Peptide Initiation Factors; D016601:RNA-Binding Proteins; D000097574:Eukaryotic Translation Initiation Factor 5A
Gastric cancer; Immunohistochemical; Prognosis; eIF5A-2